[Prostate cancer with BRCA2 pathogenic mutation: a clinicopathological analysis].

D H Wang1, W L Yin1, X Y Pan1

  • 1Department of Pathology, West China Hospital, Sichuan University, Chengdu 610041,China.

Summary

BRCA2 gene mutations are common in aggressive prostate cancers. While DNA damage repair gene mutations shorten survival, BRCA2 mutations did not significantly impact overall survival in this study.